# PRINCE (NCT03658447)

> PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)

No report yet. It can be ordered.

- Indication: metastatic castration resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03658447
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Metastatic Castration Resistant Prostate Cancer
- Interventions: Pembrolizumab; 177Lu-PSMA
- Enrollment: 37
- Primary outcome: Prostate Specific Antigen (PSA) response
- Primary outcome: Incidence of Treatment-Emergent Adverse Events [Safety]
- Primary outcome: Tolerability

## Indexed commentary on PRINCE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=prince-nct03658447